High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy

Thomas H. Brannagan, Armin Alaedini, Douglas E. Gladstone

Research output: Contribution to journalArticlepeer-review


Patients with multifocal motor neuropathy (MMN) respond to intravenous immune globulin (IVIg) and cyclophosphamide, although the benefit is not sustained. High-dose cyclophosphamide can induce a remission in patients with autoimmune diseases, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We describe a patient with refractory MMN who improved with high-dose cyclophosphamide (50 mg/kg for 4 days) without stem cell rescue. Following treatment she discontinued IVIg. At a 6-month examination, her strength had improved and she had regained the ability to write. High-dose cyclophosphamide may be a successful treatment for patients with MMN refractory to other therapies.

Original languageEnglish (US)
Pages (from-to)246-250
Number of pages5
JournalMuscle and Nerve
Issue number2
StatePublished - Aug 1 2006
Externally publishedYes


  • Autoimmune disease
  • Conduction block
  • Cyclophosphamide
  • GM1 antibodies
  • Multifocal motor neuropathy

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)


Dive into the research topics of 'High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy'. Together they form a unique fingerprint.

Cite this